Technical Analysis for NTLA - Intellia Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 13.3 -1.70% -0.23
NTLA closed down 1.7 percent on Friday, November 15, 2019, on 84 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical NTLA trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Bearish Engulfing Bearish -1.70%
Wide Bands Range Expansion -1.70%
Overbought Stochastic Strength -1.70%
Stochastic Reached Overbought Strength -4.59%
Wide Bands Range Expansion -4.59%
Overbought Stochastic Strength -4.59%
Upper Bollinger Band Touch Strength -4.59%
NR7 Range Contraction 2.47%

Older signals for NTLA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. It has a strategic collaboration and license agreement with Novartis focused on the development of new ex vivo CRISPR/Cas9-based therapies. Intellia Therapeutics Inc. was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Medicine Biotechnology Biology Immune System Emerging Technologies Molecular Biology Genetics Inborn Errors Of Metabolism Genome Editing Liver Diseases Antitrypsin Deficiency Chimeric Antigen Receptor Cas9 CRISPR Transthyretin Amyloidosis
Is NTLA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 19.0
52 Week Low 10.26
Average Volume 497,510
200-Day Moving Average 15.0818
50-Day Moving Average 12.6925
20-Day Moving Average 12.4193
10-Day Moving Average 13.162
Average True Range 0.7589
ADX 34.59
+DI 25.2142
-DI 9.6508
Chandelier Exit (Long, 3 ATRs ) 11.9533
Chandelier Exit (Short, 3 ATRs ) 13.0467
Upper Bollinger Band 14.3303
Lower Bollinger Band 10.5083
Percent B (%b) 0.73
BandWidth 30.774681
MACD Line 0.3396
MACD Signal Line 0.1536
MACD Histogram 0.186
Fundamentals Value
Market Cap 480.29 Million
Num Shares 36.1 Million
EPS -1.33
Price-to-Earnings (P/E) Ratio -10.00
Price-to-Sales 42.05
Price-to-Book 5.07
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.25
Resistance 3 (R3) 14.30 14.04 14.09
Resistance 2 (R2) 14.04 13.80 14.01 14.03
Resistance 1 (R1) 13.67 13.65 13.54 13.62 13.98
Pivot Point 13.41 13.41 13.35 13.38 13.41
Support 1 (S1) 13.04 13.17 12.91 12.99 12.62
Support 2 (S2) 12.78 13.02 12.75 12.57
Support 3 (S3) 12.41 12.78 12.51
Support 4 (S4) 12.36